

# Nymox Pharma director Robinson adds to recent significant purchases

**Nymox Pharmaceutical Corporation {NASDAQ: NYMX}** Director James George Robinson has acquired 29,854 more shares in the company, adding to his recent purchases.

All three purchases in December were quite significant, and are an excellent example of a director showing confidence in his own company.

## *Comment*

*This is a superb, and sadly very rare example of a director putting substantial funds in to back his own company.*

*He has invested around \$500,000 in December alone, he must be very confident!*

**Nymox Pharmaceutical Corporation {NASDAQ: NYMX}** Director James George Robinson acquired 29,854 shares of the stock in a transaction purchase transaction dated Wednesday, December 23rd.

The shares were bought at an average price of \$3.54 per share, with a total value of \$105,683.16. Following the completion of the purchase, the director now directly owns 2,517,550 shares

of the company's stock, valued at approximately \$8,912,127. The purchase was disclosed in a filing with the SEC.

**James George Robinson also recently made the following trades**

- Friday, December 18th, James George Robinson bought 63,334 shares of Nymox Pharmaceutical Corp stock. The stock was bought at an average cost of \$3.56 per share, for a total transaction of \$225,469.04.
- Friday, December 11th, James George Robinson bought 46,812 shares of Nymox Pharmaceutical Corp stock. The stock was bought at an average cost of \$3.51 per share, for a total transaction of \$164,310.12.

Nymox Pharmaceutical Corporation {NASDAQ: NYMX} traded up 5.85% on Thursday, hitting \$3.62. Shares traded were 226,614.

Nymox Pharmaceutical Corp has a 52-week low of \$0.35 and a 52-week high of \$4.37., and their market cap is \$134.61 million. Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (NASDAQ:NYMX) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also has a patent portfolio covering its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex conducts research and development, and manufacturing for NicAlert and TobacAlert.